Science AI Journal
Economics, Econometrics and Finance · Research topic

Open research questions in Pharmaceutical Economics and Policy

113 unresolved questions extracted from the limitations and future-work sections of 1,169 Pharmaceutical Economics and Policy papers in our library. Each links back to the study that raised it.

What the literature leaves open

  • The study faces challenges in assessing the complex effects of the NVBP policy on the quantity of GCE-certified generic drugs. The study needs to account for the time-varying effects of each intervention and the differences between the intervention group and the control group.

    Dynamic effects of China’s national volume-based procurement on generic drug consistency evaluation: An interrupted time series analysis · 2026 · DOI

  • Research on the impact of NVBP on manufacturers is still emerging and not comprehensive. There is a lack of studies on the dynamic effects of the NVBP policy on the quantity of GCE-certified generic drugs.

    Dynamic effects of China’s national volume-based procurement on generic drug consistency evaluation: An interrupted time series analysis · 2026 · DOI

  • The prices of diabetes medicines are a key determinant for access, yet little is known about the association between manufacturing costs and current market prices.

    Estimated Sustainable Cost-Based Prices for Diabetes Medicines · 2024 · DOI

  • Despite the destabilizing impact of the COVID-19 pandemic on pharmaceutical production, it remains unclear whether issues affecting the drug supply chain were more likely to result in meaningful shortages during the pandemic.

    Drug Shortages Prior to and During the COVID-19 Pandemic · 2024 · DOI

  • One major but poorly understood dimension of integration is between physician organizations and pharmacies for self-administered drugs or in-house pharmacies.

    Trends in Integration Between Physician Organizations and Pharmacies for Self-Administered Drugs · 2024 · DOI

  • The study only considers a specific period and may not be generalizable to other time periods. The study relies on publicly available data and may be limited by data quality.

    France versus Germany: differences and similarities in determining the added therapeutic value of medicines · 2026 · DOI

  • Prior studies have not compared decisive appraisals of G-BA and HAS. There is a need for a comprehensive comparison of the added therapeutic value of medicines in France and Germany.

    France versus Germany: differences and similarities in determining the added therapeutic value of medicines · 2026 · DOI

  • Further study on the impact of digital health technologies on Product Lifecycle Management (PLM), - Exploration of the growth of biosimilars and their effect on the pharmaceutical industry

    Product Life Cycle Management and Strategies for Aging Products in Pharmaceutical Marketing · 2026 · DOI

  • The need for effective strategies to manage aging products in the pharmaceutical industry, - The importance of understanding the challenges of Product Lifecycle Management (PLM)

    Product Life Cycle Management and Strategies for Aging Products in Pharmaceutical Marketing · 2026 · DOI

  • The study identifies a gap in the current understanding of the role of Japanese subgroup data in the regulatory approval process for oncology drugs in Japan. The gap is related to the lack of analysis of the impact of Japanese subgroup data on the approval of oncology drugs in Japan.

    Impact of Japanese Subpopulation Data and Overall Survival in Pivotal Trials on Oncology Drug Approvals in Japan · 2026 · DOI

  • In this research, only approved new drugs were captured. In other words, it should be noted that products for which approval was denied, applications for which approvals were withdrawn, and applications for which approvals were abandoned in Japan were not captured. It should be con- sidered the possibility that sponsors submit only products with high likelihood of approval in Japan. In addition, the impact of the difference in safety profiles between Japan and overseas on the approval in Japan was outside the scope of this research. Author contributions All authors contributed to the conception and design of the research, and to the analysis and interpretation of the data. All authors contributed to the critical revisions for publication. Funding None. Data Availability No datasets were generated or analysed during the current study.

    Impact of Japanese Subpopulation Data and Overall Survival in Pivotal Trials on Oncology Drug Approvals in Japan · 2026 · DOI

  • Future research should explore broader green finance measures as firm-level green credit data becomes more systematically available through enhanced environmental information disclosure requirements. This points to possible policy tools for pursuing the dual goals of environmental sustainability and health equity envisioned in the Sustainable Development Goals (SDGs), although direct evidence on health outcomes remains to be established. The mechanisms found in this study are primarily rooted in the context of China, and the cross-country generalizability the findings still needs to be validated. The research sample is limited to A-share listed pharmaceutical companies.

    Digital transformation, green finance, and pharmaceutical affordability in China: a health economics perspective · 2026 · DOI

  • The complexity of the US pharmaceutical market. The controversy surrounding PBMs. The need to analyze the role of PBMs in the market.

    Common Agent or Double Agent? Pharmacy Benefit Managers in the Prescription Drug Market · 2026 · DOI

  • There is a need to understand the relationship between essential medicine status and shortages. There is a lack of research on medicine supply issues in Japan.

    Japan essential medicine list and medicine supply issues: a cross-sectional study · 2026 · DOI

  • The paper suggests future research directions on the pharmaceutical commons, including the development of new partnership models and the investigation of the impact of pharmaceutical commons on access to medicines. The paper highlights the need for further research on the characteristics of pharmaceutical commons and their implications for the pharmaceutical sector.

    The pharmaceutical commons: conceptual clarifications, a practice example, and a research agenda · 2026 · DOI

  • The paper identifies a gap in the conceptualization of the pharmaceutical commons. The paper identifies a need for a consistent conceptual vocabulary and a research agenda on the pharmaceutical commons. The paper highlights the importance of developing alternative modes of organizing pharmaceutical research and deployment.

    The pharmaceutical commons: conceptual clarifications, a practice example, and a research agenda · 2026 · DOI

  • The study notes that the treatment of obstructive airway diseases is subject to changes in clinical practice and systemic conditions. The analysis is limited by the use of packages as a measure of consumption.

    Analysis of drug reimbursement costs for medications used in the pharmacotherapy of obstructive airway disease in Poland in 2022-2024 · 2026 · DOI

  • The study notes that the results are approximate due to the use of packages as a measure of consumption. The analysis is limited to the Polish healthcare system.

    Analysis of drug reimbursement costs for medications used in the pharmacotherapy of obstructive airway disease in Poland in 2022-2024 · 2026 · DOI

  • Established pharmaceutical innovation theory does not fully account for hospital and university trials. A new theory is needed to explain the large numbers of hospital and university trials.

    THE REPUBLIC OF TRANSLATIONAL MEDICINE · 2026 · DOI

  • OPEN QUESTIONS AND THE FUTURE OF THE REPUBLIC The emergence of the Republic model presents society with options. In doing so, it takes some of the first steps towards filling a 30-year gap in the literature, explaining the incentives and resources that underpin the Republic and situating it within a potential shift towards a new model of translational medicine.

    THE REPUBLIC OF TRANSLATIONAL MEDICINE · 2026 · DOI

  • Forgetfulness, physical problems, or lack of understanding of the condition or medicines may influence patients' adherence to their therapy. Inadequate government reimbursement is a barrier to pharmacist provision of DAA services. A cap on the number of funded DAA services per pharmacy is a barrier to pharmacist provision of DAA services.

    Community Pharmacist Preferences for Providing a Dose Administration Aid Service in Australia: A Discrete Choice Experiment · 2026 · DOI

  • There is a lack of understanding of how pharmacists perceive DAA benefits and challenges. The study aims to address this gap by exploring community pharmacists' preferences for attributes of a DAA service.

    Community Pharmacist Preferences for Providing a Dose Administration Aid Service in Australia: A Discrete Choice Experiment · 2026 · DOI

  • There is a need for a study that examines the trend and seasonality components of pharmaceutical expenditures in Türkiye. There is a need for a study that provides a projection for the period from 2025 to 2030.

    Forecasting Reimbursed Pharmaceutical Expenditures in Türkiye: 2025-2030 Projection · 2026 · DOI

  • The agreement may weaken indication-level value signalling. The agreement constrains routine utilisation monitoring. The agreement may distort comparator pricing in future economic evaluations.

    Balancing Access and Value in Multi-Indication Medicines: Implications of PD-L1 Broad Listings in Australia · 2026 · DOI

  • The evaluation of multi-indication medicines poses significant challenges for health technology assessment. There is a need for novel reimbursement approaches to ensure timely subsidised access to these medicines.

    Balancing Access and Value in Multi-Indication Medicines: Implications of PD-L1 Broad Listings in Australia · 2026 · DOI

Most-cited papers in Pharmaceutical Economics and Policy

Most recent work

Find a gap in your own Pharmaceutical Economics and Policy sub-topic

This page shows what the Pharmaceutical Economics and Policy literature already flags as unresolved. To narrow it to your specific question, run the guided finder — it searches the gap library on demand and checks candidates against 250M+ OpenAlex works.

Open the Research Gap Finder →

Related topics in Economics, Econometrics and Finance

Labor market dynamics and wage inequality
862 open questions
Global trade and economics
603 open questions
Housing, Finance, and Neoliberalism
568 open questions
Economic Theory and Institutions
528 open questions
Regional Economics and Spatial Analysis
507 open questions
Monetary Policy and Economic Impact
490 open questions
Historical Economic and Social Studies
476 open questions
Economic Growth and Productivity
474 open questions
113 open questions have been extracted from the limitations and future-work passages of 1,169 Pharmaceutical Economics and Policy papers in our library. Each one below links back to the study that raised it, so you can read the original claim in context.

Tools for your next paper

Gaps & Literature SearchFind open questions in any field — 120,000+ open gaps mined from our own library.Pre-CheckIs your paper ready? A Tier 1–5 acceptance probability in seconds.Journal FinderA ranked shortlist of target journals from a 17,500-venue index.Duplicate Publication CheckerCheck prior-publication & salami-slicing risk across 8 sources.Citation GeneratorFreeA DOI or title → APA, MLA, Vancouver, Chicago, BibTeX, RIS. No signup.Graphical Abstract MakerFreeTurn your findings into a colorblind-safe graphical abstract.

Compare the category — Honest roundups of the AI research tools, ours listed alongside the alternatives.

Command palette

Jump anywhere, run any action.